MSLN Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
MSLN Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This MSLN target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP. It turns target biology, disease context, clinical validation, competitive intensity, and IP strategy into a repeatable target evaluation workflow for life sciences AI agents.
Explore PatSnap Life Sciences MCP Servers
Target MSLN UniProt Q13421 | Target-linked drugs 218 154 active development drugs | Ovarian cancer trials 48 MSLN + ovarian cancer MCP query | Released results 14 Clinical result query |
Executive View
MSLN is a biologically plausible and clinically active ovarian cancer target with multiple modalities in play, including CAR-T/CAR-NK, ADCs, and bispecific antibodies. The opportunity is attractive for modality differentiation, but target expression, intratumoral heterogeneity, and safety in normal mesothelial tissues need careful positioning.
- Biology: Target & Disease MCP identifies mesothelin as a membrane-anchored protein that may play a role in cellular adhesion.
- Disease context: Ovarian cancer is a high-activity oncology indication with 941 development drugs and 1,281 roll-up development drugs in the disease record.
- Validation: Clinical Trials MCP returns 48 MSLN + Ovarian Cancer trials and 14 released result records.
- Strategy: Prioritize modality fit, antigen expression threshold, cell-therapy manufacturability, and combination strategy in platinum-resistant disease.
Scorecard
Biology confidence: Medium-high
Clinical validation: Active early clinical evidence
Competitive pressure: Moderate-to-high
White-space potential: Modality-led
Biology and Disease Rationale
Target & Disease MCP returns MSLN / mesothelin with aliases including CAK1 antigen and MPF, UniProt Q13421, 218 target-linked drugs, and 154 active development drugs. The target profile emphasizes membrane-anchored biology and cellular adhesion, making it suitable for antibody, ADC, and engineered-cell approaches when expression is enriched in tumor tissue.
For ovarian cancer, Target & Disease MCP describes tumors or cancer of the ovary and shows 941 development drugs with 1,281 roll-up development drugs. In this crowded disease setting, MSLN programs need a clear rationale in platinum-resistant disease, recurrent epithelial ovarian cancer, or biomarker-enriched patient groups.
Explore PatSnap Life Sciences MCP Servers for AI agents
Selected Trial and Result Evidence
| DUAL-OV-CAR-NK Clinical Trials MCP returned a recruiting Phase 1/2 study of dual-targeting CAR-NK cells for recurrent ovarian cancer involving MSLN, FRα, and MUC16. |
| KT032 in mesothelin-positive advanced solid tumors Not-yet-recruiting Early Phase 1 study evaluating KT032 cell injection in mesothelin-positive advanced solid tumors. |
| NI-1801 mesothelin x CD47 bispecific antibody Clinical trial result query returned a positive Phase 1 record in heavily pretreated mesothelin-expressing platinum-resistant epithelial ovarian cancer. |
| RC88 / misitatug blivedotin Released positive Phase 1/2 proof-of-concept result record for an MSLN-directed ADC program. |
IP and R&D Recommendation
MSLN IP review should map antibody and cell-therapy binders, CAR constructs, ADC linker-payload claims, bispecific formats, ovarian cancer use claims, and diagnostic thresholds for mesothelin expression.
Recommendation
MSLN is best framed as a modality-differentiation target. Strong programs should prove why their CAR, ADC, or bispecific format can overcome expression heterogeneity and safety constraints while delivering clinically meaningful benefit in recurrent or platinum-resistant ovarian cancer.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
Data note: Target biology, disease profile, clinical trial counts, trial examples, and result evidence were generated from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP queries performed on July 9, 2026.
